Data Collection
OtherQuestionnaire, Vaccination book
NCT Number: NCT01777074
The present study is conducted in order to assess the acceptability of Hepatitis B vaccination in French general practitioners and peadiatricians before and after reimbursement of the paediatric vaccine InfanrixHexa. Two data measurement time points are planned, first before reimbursement and after reimbursement.
Looking for future studies?
Notify MeAll sexes
Observational
GSK Investigational Site, Agde, France
The aim of the study is to assess the acceptability of Hepatitis B immunization among general practitioners and open-care paediatricians. This is a national, repeated transversal epidemiological study with two data measurement time-points over a period of two years (T1 in 2009, T2 in 2011, two different samples of physicians) in order to assess immunization practices before introduction of the reimbursement of InfanrixHexa®, during the transition period and then during the period following reimbursement of the vaccine. At each collection time-point, two patient age groups will be investigated: 12-15 months and 24-27 months, thus providing measurements before/after reimbursement.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Questionnaire, Vaccination book
Time frame: 4 years
Time frame: 4 years
GlaxoSmithKline
Industry
Measurement of the Changes in Acceptability of Hepatitis B Immunization Among General Practitioners and Open-care Paediatricians
Acronym: PRALINE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00004850
Blood-Borne Infections, Communicable Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06422767
Blood-Borne Infections, Communicable Diseases
Austin, Texas, United States
View Trial DetailsNCT07637214
Blood-Borne Infections, Bronchial Diseases
Wuhan, Hubei, China
View Trial DetailsNCT05551273
Blood-Borne Infections, Communicable Diseases
San Diego, California, United States
View Trial Details